Molecular epidemiology of extended-spectrum β-Lactamase-producing *Klebsiella pneumoniae* isolated from neonatal intensive care unit patients involved in hospital infection cases in Rio de Janeiro, Brazil

Marcio Martins-Loureiro,* Bianca Aguilar de Moraes,* Vivian Lorenzato-Furtado de Mendonça,* Maria Rita Rocha-Quadra,** Glenda dos Santos-Pinheiro,** Marise Dutra-Asensi*

**ABSTRACT.** During a two years period, in this study was analyzed the demographic and bacteriologic data of 42 hospitalized newborns attempted by extended-spectrum β-lactamase-producing *Klebsiella pneumoniae* sepsis in a neonatal intensive care unit of a public maternity hospital in Rio de Janeiro, Brazil. The newborns mean age was 10.4 days, with a major prevalence of hospital infection in males (55.0%) than females (45.0%), and a major frequency in vaginal delivery (65.0%) than cesarean delivery (35.0%). 31 patients (77.5%) received a mean of 3 antimicrobials during a 7.9 days before positive blood cultures. The most important underlying risk conditions were prematurely (87.5%), very low birth weight (55.0%) and asphyxia (40.0%). Among the isolated strains were detected high resistance proportion to β-lactams, aminoglycosides, chloramphenicol and trimethoprim-sulfamethoxazole. 6 distinct clones in a cluster of 42 epidemiologically related strains were detected through PFGE profiles. The isolated strains presented 9 different antimicrobial resistance profiles (ARPs), where the most frequent clones (A, B and D) were distributed in 5, 3 and 5 ARPs, respectively. Based in the PFGE profiles and isolation periods, apparently the clones A plus A1, B and D caused 3 distinct outbreaks during the study period.

Key words: *Klebsiella pneumoniae*, extended-spectrum β-lactamase, hospital infection, sepsis.

**INTRODUCTION**

*Klebsiella pneumoniae* is a pathogen, able to infect debilitated and immunocompromised patients, and newborns, especially those with a risk factors to acquire hospital infection (HI) in a neonatal intensive care units (NICU). *K. pneumoniae* infections are associated with a significantly increase in the hospitalization costs related to patient treatment, morbidity and mortality rates.4,19,24,32

In addition to host factors, bacterial virulence determinants, as capsular polysaccharide, the aerobactin-mediated iron uptake system, the mucoid phenotype, and the toxic lipopolysaccharide, contribute to the outcome of *K. pneumoniae* infections.24

*K. pneumoniae* is a pathogen that frequently presents resistance to cephalosporins through the production of extended-spectrum β-lactamases (ESBL),5,24 that are encoded mainly by SHV and/or TEM genes.37 Generally, these genes are harbored on transferable plasmids, that often carry other resistance factors, including resistance to aminoglycosides.39
These plasmids can be transferred to others species of the Enterobacteriaceae family during outbreaks.2,5,8

The epidemiology of *K. pneumoniae* infections are usually studied by the analysis of phenotypic markers, including biotypes, serovars and antimicrobial susceptibility patterns.5,20,22 However, with the advent of molecular microbiology technologies, nucleic acid-based methods have been used to assist identification of bacteria to subspecies level in epidemiological studies, providing a higher discriminating power than phenotypic data.20,22

The chromosomal DNA analysis by pulsed field gel electrophoresis (PFGE) is worldwide considered the most powerful tool for the study of the hospital epidemiology of *K. pneumoniae* due to its high discriminatory capacity, good reproducibility and easy interpretation. These technique facilitates the elucidation of transmission routes, genetic variability, phylogenetic distances between strains and can give insight into the interrelationship of bacterial isolates.5,20,22

This study reports the demographics data of the hospitalized newborns attempted by ESBL-producing *K. pneumoniae* sepsis associated with HI, during a period ranged from July 1997 to July 1999, in a NICU of a public maternity hospital from Rio de Janeiro, Brazil. As well as determine the rates of antimicrobial resistance, the antimicrobial resistance profiles and PFGE patterns of the isolated strains during this period.

**MATERIAL AND METHODS**

**Bacterial strains, patients and hospital.** 42 ESBL-producing *K. pneumoniae* strains isolated from blood cultures of newborns involved in HI well documented cases, between July 1997 and July 1999, at Hospital Maternidade Alexander Fleming II (HMAF) were analyzed. HMAF is a maternity hospital in Rio de Janeiro, Brazil, providing assistance and perinatal cares, including a neonatal intermediate care unit with 40 beds and a NICU with 15 beds. HI were defined by CDC standard definitions5 adapted to neonatal pathology. In general, infections that occurred after 48 h of hospitalization were assumed to be acquired in the hospital, but each instance of infection was considered individually because of the late onset of some perinatal acquired infections.

**Blood cultures, strains identification and susceptibility testing.** 0.2 ml of venous blood obtained from newborns were drawn into bottles with 10 ml of supplemented TSB (Roche) and incubated at 37°C. After 24 h, the blood cultures were inoculated into Thioglycolate Broth (Difco Laboratories, Detroit, Mich.), and plated onto Blood Agar and EMB Agar (Difco Laboratories, Detroit, Mich.) during a period ranging from 1 to 7 days. The *K. pneumoniae* strains identification was performed according to Ewing,7 using classical biochemical tests.

The antimicrobial susceptibility test were carried out using the disk diffusion method according to National Committee for Clinical Laboratory Standards (NCCLS) recommendations.29 Quality control was carried out using standard strains of *Escherichia coli* (ATCC 25922), *Pseudomonas aeruginosa* (ATCC 27953) and *Staphylococcus aureus* (ATCC 25923). Concentrations of antimicrobial drugs used were: cephalothin (30 µg), cefoxitin (30 µg), ceftaxime (30 µg), cefuroxime (30 µg), imipenem (10 µg), gentamicin (10 µg), amikacin (30 µg), ciprofloxacin (5 µg), trimethoprim-sulfamethoxazole (1.25/23.75 µg), chloramphenicol (30 µg), tetracycline (30 µg). The phenotypic detection of ESBL production were performed using E-test strips (AB Biodisk, Solna, SW).

**PFGE.** The chromosomal DNA restriction analysis of the strains were performed by PFGE. Chromosomal DNA extraction of the strains were performed according to procedure previously described by Sader et al.36 Nucleic acids included into agarose plugs were digested with 40 U of XbaI restriction enzyme at 37°C during 20 h. Electrophoresis in agarose gels was performed at 6 V/cm during 24 h in 0.5X TBE buffer at 13°C with a ramping switch time of 10-70 sec with a CHEF DR III pulsed field electrophoresis system (Bio-Rad, Laboratories, Richmond, Calif.). Fragments were stained with ethidium bromide and photographed. All agarose gels were performed twice to verify the reproducibility of the tests.

Band patterns were analyzed using GelCompar II (Applied Maths, Belgium), any internal markers were used. Relations between fingerprints were determined by construction of a similarity matrix using the Dice’s coefficient with 1.5% position tolerance, which generated a dendrogram using the UPGMA clustering algorithm. Clonal structure definitions of the *K. pneumoniae* strains were made according to Tenover et al.38

**Epidemiological analysis of patients.** For each HI case an epidemiological record with demographics and microbiologic data was done, unfortunately demographic data from two newborns were not available. Data were collected in Excel 7.0 software (Microsoft) and analyzed in Epi-Info (version 6.04b; CDC, Atlanta, USA).

**RESULTS**

*K. pneumoniae* were the most frequent pathogen isolated from NICU patients in the HMAF, accounting 22.9% (69/301) of the isolates during two years period (07/97 to 07/99). From these 69 isolates, 42 strains were ESBL-producers accounting a total of 60.9% of the isolated *K. pneumoniae* strains in this period (data not shown).
Table 1 shows the general demographic characteristics of the hospitalized newborns in NICU-HMAF, Rio de Janeiro, Brazil, affected by ESBL-producing *K. pneumoniae* sepsis and classified as HI cases. The newborns mean age was 10.4 days. Major prevalence of IH in males (55.0%) than females (45.0%), as well as a major frequency in vaginal delivery (65.0%) than cesarean delivery (35.0%) was verified. 31 (77.5%) newborns received antimicrobial drugs before positive blood cultures presentation with mean use of 3.0 antimicrobials per patient during 7.9 days. The most important underlying risk conditions were prematurity (87.5%), very low birth weight (55.0%), asphyxia (40.0%) and hyaline membrane disease (25.0%).

A total of 13 different antimicrobials (Table 2) were used for treatment of 31 (77.5%) patients before positive blood cultures presentation, with the highest frequency of use for ampicillin (29/31 patients; 93.5%), amikacin (27/31; 87.1%), cefotaxime (11/31; 35.5%) and oxacillin (10/31; 32.2%).

The analysis of the antimicrobial resistance percentages (Table 3) showed a high antimicrobial resistance percentage (70 to 100%) to cephalotin, ceftriaxone, cefuroxime, gentamicin, amikacin, chloramphenicol and trimethoprim-sulfamethoxazole in the two analyzed periods (07/97 to 07/98 and 08/98 to 07/99). High antimicrobial resistance percentage to tetracycline was detected only in the second period (72.7%). A low antimicrobial resistance percentage to cefoxitin (3.2% in first year and 18.2% in second) and no strain resistant to imipenem and ciprofloxacin were demonstrated in both periods.

Table 1. Demographic characteristics of the hospitalized newborns in two years period (07/97 to 07/99).

<table>
<thead>
<tr>
<th>Demographics data</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10.4 days</td>
</tr>
<tr>
<td>Male Sex&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22/40 (55.0%)</td>
</tr>
<tr>
<td>Female Sex&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18/40 (45.0%)</td>
</tr>
<tr>
<td>Vaginal delivery&lt;sup&gt;a&lt;/sup&gt;</td>
<td>26/40 (65.0%)</td>
</tr>
<tr>
<td>Cesarean delivery&lt;sup&gt;a&lt;/sup&gt;</td>
<td>14/40 (35.0%)</td>
</tr>
<tr>
<td>Twins&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1/40 (2.5%)</td>
</tr>
<tr>
<td>Patients in antimicrobial drugs use before positive blood cultures presentation&lt;sup&gt;a&lt;/sup&gt;</td>
<td>31/40 (77.5%)</td>
</tr>
<tr>
<td>Mean of antimicrobial drugs used by patients before positive blood culture presentation&lt;sup&gt;b&lt;/sup&gt;</td>
<td>94/31 (3.0)</td>
</tr>
<tr>
<td>Mean of antimicrobial days use before positive blood culture presentation&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.9 days</td>
</tr>
</tbody>
</table>

Underlying risk conditions

<table>
<thead>
<tr>
<th></th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prematurity&lt;sup&gt;a&lt;/sup&gt;</td>
<td>35/40 (87.5%)</td>
</tr>
<tr>
<td>Very low birth weight (VLBW; &lt; 1500 g)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22/40 (55.0%)</td>
</tr>
<tr>
<td>Asphyxia&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16/40 (40.0%)</td>
</tr>
<tr>
<td>Hyaline Membrane Disease&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10/40 (25.0%)</td>
</tr>
<tr>
<td>Prolonged amniotic membrane rupture time (PAMR; &gt; 24 hs)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8/40 (20.0%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Data from 40 patients. <sup>b</sup>Data from 31 patients who received antimicrobial drugs before positive blood culture presentation.

Table 2. Antimicrobial drugs administrated to newborns before positive blood culture presentation in a two years period (07/97 to 07/99).<sup>a</sup>

<table>
<thead>
<tr>
<th>Antimicrobials</th>
<th>Frequency</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin</td>
<td>29</td>
<td>93.5</td>
</tr>
<tr>
<td>Amikacin</td>
<td>27</td>
<td>87.1</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>11</td>
<td>35.5</td>
</tr>
<tr>
<td>Oxacillin</td>
<td>10</td>
<td>32.2</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>3</td>
<td>9.7</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>3</td>
<td>9.7</td>
</tr>
<tr>
<td>Imipenem</td>
<td>3</td>
<td>9.7</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>2</td>
<td>6.4</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>2</td>
<td>6.4</td>
</tr>
<tr>
<td>Amphotericin</td>
<td>1</td>
<td>3.2</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>1</td>
<td>3.2</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>1</td>
<td>3.2</td>
</tr>
<tr>
<td>Penicilina</td>
<td>1</td>
<td>3.2</td>
</tr>
<tr>
<td>Total</td>
<td>94</td>
<td>—</td>
</tr>
</tbody>
</table>

<sup>a</sup>Data from 31 hospitalized newborns who received antimicrobial drugs before positive blood culture presentation.

Table 3. Antimicrobial resistance percentage detected in 42 isolated *K. pneumoniae* strains during two years period (07/97 to 07/99).

<table>
<thead>
<tr>
<th>Antimicrobials</th>
<th>07/97 to 07/98&lt;sup&gt;b&lt;/sup&gt;</th>
<th>08/98 to 07/99&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cephalothin</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Cefotixin</td>
<td>3.2</td>
<td>18.2</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Imipenem</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>80.6</td>
<td>100</td>
</tr>
<tr>
<td>Amikacin</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>96.8</td>
<td>100</td>
</tr>
<tr>
<td>Trimethoprim/sulfamethoxazole</td>
<td>90.3</td>
<td>100</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>29.0</td>
<td>72.7</td>
</tr>
</tbody>
</table>

<sup>b</sup>31 strains were isolated during this period. 11 strains were isolated during this period.
Figure 1 shows 6 distinct clones (A, A1, B, C, D and E) detected in a cluster of 42 epidemiologically related strains through of PFGE. These clones were isolated during a two years period, with the highest frequency of isolation for clone A (15 strains; 35.7%), followed by clones D and B with frequencies of 30.9% and 23.8% respectively. Isolation of the clones A1, C and E accounted for 9.5% of the isolated strains.

The dendrogram generated by GelCompar II (Figure 2), revealed that the clones A and A1 are genetically related (similarity percentage >95%), and genetically unrelated to the others clones (similarity percentage <80%), under stringency conditions above cited. In general, the detected clones presented low cophenetic correlation (44.7%). Four clones (A, A1, D and E) were detected in the first year of analysis, whereas two clones (B and C) were isolated in the second year.

The distribution of the isolated strains according to their antimicrobial resistance profiles (ARP) and PFGE profiles (Table 4), demonstrated 9 ARPs with resistance ranged from 6 to 9 different antimicrobials. Isolated strains associated to profile 4 (42.8%) had resistance to 7 antimicrobials, followed by the profiles 7 (26.1%) and 1 (9.5%) had resistance to 8 and 6 antimicrobials respectively. In relation to distribution of the more frequent clones (A, D and B) in the ARPs, we verified that the clone A was distributed in 5 different ARPs (2, 4, 5, 6 and 7); the clone D was detected in 5 ARPs (1, 3, 4, 7 and 8); and the clone B was observed in 3 ARPs (4, 7 and 9).

DISCUSSION

Nosocomial sepsis are among the most common nosocomial infections, and are a major problem for newborns admitted to intensive care units. These infections, associated to immaturity and invasive procedures, cause a greater need for patient cares and handling. In this study, realized between July 1997 to July 1999, the hospitalized newborns affected by ESBL-producing K. pneumoniae sepsis...
at HMAF presented some risk conditions for HI acquisition. The most predominant were submission to various invasive procedures (tracheal intubations, mechanical ventilation, respiratory ways aspiration, intravascular catheters, parenteral nutrition), and presence of underlying risk conditions (prematurity, asphyxia, hyaline membrane disease, very low birth weight, small gestational age, and prolonged amniotic membrane rupture of the mothers, birth defects, etc.). Routinely, the analyzed newborns presented association of diverse risk factors during their stay in the NICU from HMAF. These observations agree with several authors, who described risk conditions to HI acquisition in NICUs.4,12,19,32,35,39

In this study, a large number of patients (77.5%) received a mean of 3 antimicrobial drugs during 7.9 days before positive blood culture presentation, due to the clinical picture suggestive of sepsis. In these cases, the first scheme of therapeutic treatment adopted in our institution was ampicillin plus amikacin, followed by oxacillin plus cefotaxime (second scheme). Empirical treatment according to schemes previously adopted in hospital routine induced selective pressures to select of multi-drug resistant strains. Several authors described that prolonged use of antimicrobials before and during NICU stay can lead to selection of ESBL-producing K. pneumoniae strains, resulting in treatment failure, due to indiscriminate use of extended spectrum β-lactams and aminoglycosides principally.4,6,17,20,25,28,32,33,35

The first empirical antimicrobial treatment scheme (ampicillin plus amikacin) reserves the use of more potent antimicrobials after culture confirmation and antimicrobial susceptibility tests, to control the emergence of resistant mutants to third generation cephalosporins, ciprofloxacin and imipenem. Cordero, Sananes and Ayers4 recommend the monitoring and restrict use of antimicrobials, because imipenem and cephalosporins induce β-lactamase production very rapidly and efficiently. Other authors6,13,37 described in ICUs that the low levels of antimicrobial resistance among K. pneumoniae to cephalosporins, aminoglycosides, imipenem and fluoroquinolones were due to still restricted use of these drugs in the unit.

K. pneumoniae is the most frequent pathogen isolated from nosocomial sepsis in the NICU-HMAF, accounting a total of 22.9% (69/301) of the isolates in a two years period, and 60.9% of these strains were ESBL-producers. This high rate of ESBL-producing K. pneumoniae in our NICU is more elevated than existing in other hospitals located on North America, Europe and Latin America.25,28,34,35

The analysis of the antimicrobial resistance demonstrated that cephalothin, ceftriaxone, cefuroxime, gentamicin, amikacin, chloramphenicol and trimethoprim-sulphamethoxazole are not effective agents for treatment of sepsis caused by ESBL-producing K. pneumoniae in HMAF, due the high resistance rates detected during two years period. Also, were detected percentage of resistance to tetracycline in the second year of the study, even though this drug is not used in HMAF routine. Some authors8,15,23,27 related the high resistance rates to these drugs with the presence of transferable plasmids commonly harbored in K. pneumoniae strains. These plasmids generally carry SHV and/or TEM genes encoding ESBLs production and other resistance factors, including resistance to aminoglycosides, chloramphenicol, tetracycline and trimethoprim-sulphamethoxazole.

Table 4. Distribution of the 42 isolated K.pneumoniae strains according to the antimicrobial resistance profiles and PFGE profiles detected in two years period (07/97 to 07/99).

<table>
<thead>
<tr>
<th>ARP number</th>
<th>ARP</th>
<th>N (%)</th>
<th>Isolated clones (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CFL/CRO/CRX/AMI/CLO/SXT</td>
<td>4 (9.5)</td>
<td>D (3), E (1)</td>
</tr>
<tr>
<td>2</td>
<td>CFL/CRO/CRX/GEN/AMI/SXT</td>
<td>1 (2.4)</td>
<td>A (1)</td>
</tr>
<tr>
<td>3</td>
<td>CFL/CRO/CRX/GEN/AMI/CLO</td>
<td>1 (2.4)</td>
<td>D (1)</td>
</tr>
<tr>
<td>4</td>
<td>CFL/CRO/CRX/GEN/AMI/CLO/SXT</td>
<td>18 (42.2)</td>
<td>A (8), B (2), C (1), D (7)</td>
</tr>
<tr>
<td>5</td>
<td>CFL/CRO/CRX/GEN/AMI/CLO/TET</td>
<td>2 (4.8)</td>
<td>A (2)</td>
</tr>
<tr>
<td>6</td>
<td>CFL/CRO/CRX/AMI/CLO/SXT/TET</td>
<td>2 (4.8)</td>
<td>A (2)</td>
</tr>
<tr>
<td>7</td>
<td>CFL/CRO/CRX/GEN/AMI/CLO/SXT/TET</td>
<td>11 (26.1)</td>
<td>A (2), A1 (2), B (6), D (1)</td>
</tr>
<tr>
<td>8</td>
<td>CFL/CRO/CRX/GEN/AMI/CLO/SXT</td>
<td>1 (2.4)</td>
<td>D (1)</td>
</tr>
<tr>
<td>9</td>
<td>CFL/CRO/CRX/GEN/AMI/CLO/SXT/TET</td>
<td>2 (4.8)</td>
<td>B (2)</td>
</tr>
</tbody>
</table>

We detected low resistance percentage to cefoxitin in two years of analysis, and these results demonstrate the emergence of resistant strains to this drug. The resistance mechanisms to cefoxitin and others cephalosporins, and the increase of the ciprofloxacin MIC in \textit{K. pneumoniae} correspond to production of class C \beta-lactamase (AmpC-type \beta-lactamases) and/or reduced or null production of the OmpK35 and OmpK36 porins, that decrease the penetration of the drugs through of outer membrane.\textsuperscript{1,10,14-16,18,27,30} \textsuperscript{Martínez-Martínez et al.}\textsuperscript{27}, suggested that cefoxitin may not be suitable for treatment of the ESBL-producing \textit{K. pneumoniae}, because mutants selected \textit{in vitro} that lack porins are resistant to cefoxitin. Cefoxitin-resistant porin-deficient mutants are easily selected \textit{in vitro} and show decreased susceptibilities to other \beta-lactams, including expanded-spectrum cephalosporins.

According with our results, ciprofloxacin and imipenem were considered the most effective agents for treatment of ESBL-producing \textit{K. pneumoniae} sepsis at HMAF, because no resistant strain to these drugs was detected during the analysis period. These antibiotics are used in HMAF routine only as the last option after antimicrobial susceptibility test and culture results, due to imipenem induce the ESBL production very rapidly and efficiently,\textsuperscript{4} and ciprofloxacin is not yet licensed for use in children due to its demonstrated toxicity to cartilage and central nervous system in animal models.\textsuperscript{21} Several authors,\textsuperscript{13,17,27,34,35} consider these drugs as potent agents in treatment of sepsis caused by these strains, principally imipenem, because this drug is effective even against porin-less mutants, due to the small size of the molecule and its zwitterionic structure, which facilitates its diffusion through the outer membrane.

\textit{K. pneumoniae} strains could be grouped in 6 branches according to their EFLP profiles, most strains belonging to groups A, D, and B. 9 different ARPs, with resistance to antimicrobials, were included in two different families, characterizing the strains as multi-drug resistant. This fact suggest the presence of different antimicrobial resistance mechanisms, that have been commonly described in \textit{K. pneumoniae} (enzymes production, efflux pump mechanism, and loss of porins or mutations in porin-encoding genes).\textsuperscript{1,10,15,16,25,27} This reinforce the idea of resistance development principally by horizontal gene transfer, gene rearrangements and enzyme overproduction.\textsuperscript{1,2,5,8,10,14-16,20,25,27,32,40} Detection of strains belonging to same clone with different ARPs is very common, because ARPs analysis are not considered as a satisfactory method for the typing of \textit{K. pneumoniae}, due the insufficient discriminatory power, poor reproducibility, horizontal transfer of genes, presence of diverse resistance mechanisms and inadequate ability to distinguish different strains.\textsuperscript{1,5,10,14,16,20-22,27}

The clones A and D (the most frequent clones), plus clone A1 (clone genetically and epidemiologically related with the clone A) and clone E, had a isolation period limited to the first year of the analysis, probably because all reservoirs were eliminated from the hospital environment. Adoption of reinforcement measures to HI prevention, such as contact isolation, suitable handwashing, gloving and gown use for management of the newborns, treatment of the infected newborns, elimination of possible contamination reservoirs and transmission routes were important decisions. These strategies initiated in May 1998 were adopted in NICU-HMAF to control a methicillin-resistant \textit{Staphylococcus aureus} outbreak, previously described.\textsuperscript{26} Two months after reinforcement of the prevention and control measures, new sepsis cases caused by ESBL-producing \textit{K. pneumoniae} were not detected. However, the clone B started to be isolated in the NICU four months after (September 1998). For this clone, the implementation of these measures of prevention and control was not effective to prevent infections.

Hands carriage is largely related in the literature as the principal transmission route of ESBL-producing \textit{K. pneumoniae} strains in NICUs, because the digestive tract of newborns is recognized as the principal reservoir of the bacteria.\textsuperscript{5,8,33,39} This reinforces the idea that the measures of HI control and prevention used to control the MRSA outbreak were able to eliminate the \textit{K. pneumoniae} clones A, A1, D and E from NICU.

The PFGE profiles and respective isolation periods demonstrated that the most frequent clones isolated in NICU-HMAF (clone A plus A1, D and B) were responsible for three distinct outbreaks occurred in July 1997 to July 1998 (clone A plus A1); July 1997 to April 1998 (clone D); and September 1998 and July 1999 (clone B). Apparently clones A plus A1 and D caused parallel outbreaks during the first year of analysis. The identification of genetically unrelated clones in a cluster of 42 epidemiologically related strains, is due to the detection of these 3 distinct outbreaks. However, many authors\textsuperscript{2,3,5,10,11,31,33,39} related that outbreaks occurred in periods ranging from three months to two years, were caused by a single strain or by genetically related strains. Outbreaks caused by different clones were associated with strains isolated from different hospitals, departments or wards; and that genetic polymorphism was associated with epidemiologically unrelated strains or epidemiologically related strains isolated from different clinical specimens.

These results reinforce the necessity of to use more accurate sub-typing methods as PFGE, because the identification of these outbreaks only were possible after application of this technique. Others authors\textsuperscript{2,5,22,25,35} recommend the use of this technique because it facilitates the study of transmission routes, genetic variability, phylogenetic dis-
stances between strains and can give insight into the interrelationship of bacterial isolates.

The observations related in this study, emphasize the need for appropriate epidemiological monitoring of ESBL-producing K. pneumoniae and other strains implicated in nosocomial infections, by using both traditional and molecular methods. As well, monitoring of resistance to broad-spectrum antimicrobials in hospital environment is necessary to control antimicrobial use, reinforce educational measures for prevention of nosocomial transmission, and elimination of possible contamination reservoirs.

ACKNOWLEDGMENTS

Financial support: CNPq and Papes (Fiocruz).

REFERENCES


27. Martins-Loureiro et al. Molecular epidemiology of Klebsiella pneumoniae

Rev Latinoam Microbiol 2001; 43 (2): 88-95

Molecular epidemiology of Klebsiella pneumoniae

94

M. Martins-Loureiro et al.
on, W. J. Martone, F. C. Tenover, R. P. Gaynes, and the National 
Nosocomial Infections Surveillance System. 1997. Evidence of in-
terhospital transmission of extended-spectrum ß-lactam-resistant 

29. National Committee for Clinical Laboratory Standards. 1997. Per-
formance Standards for Antimicrobial Susceptibility Testing. Doc-
ument M7-A4. Villanova, PA: NCCLS.

30. Pitout, J. D. D., K. S. Thomson, N. D. Hanson, A. F. Ehrhardt, E. S. 
Moland, and C. C. Sanders. 1998. ß-lactamases responsible for re-
sistance to expanded-spectrum cephalosporins in Klebsiella pneu-
moniae, Escherichia coli and Proteus mirabilis isolates recovered 

31. Prodinger, W. M., M. Fille, A. Bauernfeind, I. Stemplingler, S. 
Aumann, B. Pfausler, C. Lass-Flörl, and M. P. Dierich. 1996. Molec-
ular epidemiology of Klebsiella pneumoniae producing SHV-5 ß-
lactamase: parallel outbreaks due to multiple plasmid transfer. J. 

32. Rojo, D., A. Pinedo, E. Clavijo, A. Garcia-Rodriguez, and V. 

33. Royle, J., S. Halasz, G. Eagles, G. Gilbert, D. Dalton, P. Jelfs, and 
D. Isaacs. 1999. Outbreak of extended spectrum ß-lactamase pro-
Fetal Neonatal. 80:64-F68.

34. Sader, H. S. 2000. Antimicrobial resistance in Brazil: comparison 
of results from two multicenter studies. BJID 4:91-99.

35. Sader, H. S., M. A. Pfaffer, R. N. Jones, G. V. Doern, A. C. Gales, 
P. L. Winokur, K. C. Kugler, and The SENTRY Latin American 
Study Group. 1999. Bacterial pathogens isolated from patients with 
bloodstream infections in Latin America, 1997: frequency of occu-
rence and antimicrobial susceptibility patterns from the SENTRY 
Antimicrobial Surveillance Program. BJID. 3:97-110.

Evaluation of interhospitalary spread of methicillin-resistant Sta-
phylococcus aureus in São Paulo, Brazil, using pulsed field gel 
electrophoresis of chromosomal DNA. Infect. Control Hosp. Epide-
miol. 15:320-323.


chromosomal DNA restriction patterns produced by pulsed-field 
gel electrophoresis: Criteria for bacterial strain typing. J. Clin. Mi-
crobiol. 33:2233-2239.

39. Van der Zwet, W. C., G. A. Parlevliet, P. H. M. Savelkoul, J. Stoof, 
A. M. Kaiser, J. G. M. Kooleman, and C. M. J. E. Vandenbroucke-
Grauls. 1999. Nosocomial outbreak of gentamicin-resistant Kleb-
siella pneumoniae in a neonatal intensive care unit controlled by a 

ity of hyperproduction of the extended-spectrum ß-lactamase SHV-

Correspondence to:

Marise Dutra Asensi
Instituto Oswaldo Cruz, Fundação Oswaldo Cruz
Departamento de Bacteriología
Laboratório de Enterobactérias
Av. Brasil 4365,
21045-900 Rio de Janeiro, RJ, Brasil
Fax: +55-21-270.6565.
E-mail marise@ioc.fiocruz.br